List of Excipients in Branded Drug XIFAXAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	XIFAXAN	rifaximin	50090-2445	CELLULOSE, MICROCRYSTALLINE
A-S Medication Solutions	XIFAXAN	rifaximin	50090-2445	EDETATE DISODIUM
A-S Medication Solutions	XIFAXAN	rifaximin	50090-2445	FERRIC OXIDE RED
A-S Medication Solutions	XIFAXAN	rifaximin	50090-2445	GLYCERYL PALMITOSTEARATE
A-S Medication Solutions	XIFAXAN	rifaximin	50090-2445	HYPROMELLOSE

Xifaxan Excipient Strategy and Commercial Opportunities for Rifaximin

Last updated: August 5, 2026

Xifaxan is a high-value oral rifaximin product whose commercial protection depends on more than the active ingredient. The formulation must preserve rifaximin's low systemic exposure, support adequate gastrointestinal delivery, maintain the intended polymorphic form, and meet product-specific bioequivalence requirements. The strongest excipient opportunities are in controlled sourcing, particle engineering, dissolution optimization, and generic or 505(b)(2) development rather than in simple substitution of common tablet ingredients.

Xifaxan is marketed by Salix Pharmaceuticals, a division of Bausch Health, in 200 mg and 550 mg tablets. The 550 mg strength is approved for prevention of overt hepatic encephalopathy recurrence and treatment of irritable bowel syndrome with diarrhea. The 200 mg tablet is approved for travelers' diarrhea caused by noninvasive strains of Escherichia coli. The product has limited systemic absorption and acts primarily within the gastrointestinal tract, making formulation performance commercially important (U.S. Food and Drug Administration [FDA], 2024a).

What excipients are used in Xifaxan tablets?

Xifaxan tablets use a conventional oral solid dosage platform with excipients selected for manufacturability, tablet integrity, color, disintegration, and dissolution.

Excipient	Likely formulation function	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	High-volume, multisource commodity; low differentiation
Sodium starch glycolate	Superdisintegrant	Important for tablet breakup and dissolution
Glycerol palmitostearate	Lubricant and processing aid	More specialized sourcing than magnesium stearate
Colloidal silicon dioxide	Glidant and moisture-control aid	Supports powder flow and content uniformity
Disodium edetate	Chelating agent and stabilizer	Potentially relevant to degradation control
Talc	Glidant, antiadherent, and processing aid	Supply qualification and regulatory-grade control are important
Propylene glycol	Processing or film-coating component	Relevant to coating performance and residual solvent control
Titanium dioxide	Opacifier and coating pigment	Regulatory and market-access considerations apply
Red iron oxide	Tablet-colorant	Supports product identification and brand differentiation

The FDA-approved labeling identifies these ingredients for the 200 mg and 550 mg tablets, although the quantity and manufacturing process are proprietary (FDA, 2024a). The commercial lesson is that the excipient list is relatively conventional, but the performance target is not necessarily conventional. Rifaximin is poorly water soluble, and dissolution behavior can be affected by particle size, solid-state form, wetting, compression force, disintegration, and coating variables.

How does rifaximin chemistry affect excipient selection?

Rifaximin is a poorly absorbed rifamycin derivative. Its low systemic exposure is part of the product's clinical profile, not merely a formulation limitation. An excipient strategy that materially increases dissolution or intestinal permeability could change local exposure, systemic pharmacokinetics, safety, or the regulatory comparability profile.

Rifaximin also exists in multiple solid-state forms. The alpha polymorph has been central to the product's formulation and patent history. Water activity, drying conditions, granulation, milling, and storage can affect solid-state stability. Excipient selection therefore has to be evaluated with the active pharmaceutical ingredient's polymorphic form rather than as an isolated compatibility exercise.

Formulation variables with the highest technical value

The most important development variables are:

1. Wetting and dissolution enhancement without materially increasing systemic absorption.
2. Maintenance of the selected rifaximin polymorph during granulation, drying, compression, and storage.
3. Rapid and reproducible tablet disintegration.
4. Low moisture uptake and low risk of hydrate or polymorph conversion.
5. Consistent gastrointestinal release under both fasting and fed conditions.
6. Robust compression at high drug loading for the 550 mg tablet.
7. Coating performance without delayed release or excessive mechanical protection.

Superdisintegrant level, lubricant selection, particle-size distribution, and granulation moisture are likely to have greater commercial significance than cosmetic coating changes.

What excipient strategies could improve Xifaxan generic development?

Generic developers should prioritize a formulation that matches the reference product's dissolution and in vivo performance without creating avoidable intellectual-property risk.

Direct-compression strategy

A direct-compression platform could reduce processing steps and manufacturing cost. Microcrystalline cellulose and colloidal silicon dioxide are compatible with this approach. The principal risks are powder flow, segregation, high-dose tablet weight, and inadequate content uniformity. The 550 mg strength is more demanding because the product must accommodate a large rifaximin load while maintaining acceptable hardness and disintegration.

Wet-granulation strategy

Wet granulation can improve flow and uniformity but introduces water and heat. Those process conditions may affect rifaximin's solid-state form. A low-moisture or nonaqueous process may be commercially attractive if it preserves the reference polymorph and produces a comparable dissolution profile.

Lipid-assisted or surfactant-assisted strategy

Lipidic excipients, surfactants, or self-emulsifying systems could increase wetting and apparent solubility. That approach may improve dissolution but creates regulatory and freedom-to-operate risks. It can also increase systemic exposure or make the formulation materially different from the reference product.

Such technology is more suitable for a differentiated 505(b)(2) product, pediatric formulation, or new dosage form than for a conventional ANDA unless the sponsor can establish an acceptable bioequivalence pathway.

Amorphous dispersion strategy

An amorphous solid dispersion could improve dissolution, but it may conflict with the reference product's solid-state profile and increase physical stability risk. It would require extensive solid-state characterization, including powder X-ray diffraction, differential scanning calorimetry, microscopy, water activity, and stability testing.

For a generic tablet, the commercial value of an amorphous dispersion is limited unless the product-specific guidance or regulatory strategy supports a materially different formulation.

What patents protect Xifaxan formulations and uses?

The Xifaxan patent estate has historically included patents directed to rifaximin polymorphs, compositions, and therapeutic uses. Frequently cited U.S. patents include:

Patent	General subject matter	Commercial relevance
U.S. Patent No. 7,045,620	Rifaximin polymorphic forms	Solid-state and form-selection risk
U.S. Patent No. 7,612,199	Rifaximin compositions and related formulation subject matter	Potential formulation overlap
U.S. Patent No. 8,309,605	Rifaximin use in hepatic encephalopathy	Relevant to the 550 mg hepatic-encephalopathy indication
U.S. Patent No. 8,642,573	Rifaximin use in IBS-related treatment	Relevant to the 550 mg IBS-D indication

The scope, status, and expiration dates must be assessed from the applicable Orange Book edition, patent records, terminal disclaimers, patent-term adjustment, and any litigation judgment. The two use patents, U.S. Patent Nos. 8,309,605 and 8,642,573, have been associated with protection extending into approximately 2029, subject to the precise claims and statutory adjustments (FDA, 2024b; U.S. Patent and Trademark Office [USPTO], n.d.).

Formulation work can create infringement exposure even when a developer avoids the active ingredient's original polymorph patent. A modified excipient system may still implicate composition, solid-state, manufacturing, or method-of-treatment claims.

When does Xifaxan lose exclusivity?

Xifaxan does not have one single exclusivity date. Market-entry analysis must separate regulatory exclusivity, listed patents, use-code restrictions, litigation outcomes, and settlement terms.

Protection category	Relevance to Xifaxan
New chemical entity exclusivity	Historical protection has expired
Orphan-drug exclusivity	Not the principal barrier for the core Xifaxan indications
Patent protection	Historically the primary barrier to competing rifaximin products
Method-of-use patents	Important for hepatic encephalopathy and IBS-D indications
Polymorph and formulation patents	Relevant to API form and tablet composition
Pediatric exclusivity	Must be checked against the current FDA record
ANDA litigation	Can delay approval or commercial launch even after submission

A generic applicant may receive FDA approval for a carved-out indication while remaining restricted from marketing for patented uses. That strategy is commercially difficult for Xifaxan because the 550 mg product's value is concentrated in the protected IBS-D and hepatic-encephalopathy indications.

What is the Orange Book status of Xifaxan?

The Orange Book identifies Xifaxan's approved products, reference-listed drug status, and patents submitted by the NDA holder. The Orange Book is the starting point for an ANDA patent-certification analysis, but it is not a complete freedom-to-operate record. Developers must also review patent prosecution histories, later-issued patents, litigation orders, claim construction, and settlement agreements (FDA, 2024b).

A formulation developer should distinguish among:

• Patents listed against the 200 mg product.
• Patents listed against the 550 mg product.
• Drug-substance or polymorph patents.
• Method-of-use patents tied to specific indications.
• Patents covering manufacturing steps or solid-state control.
• Unlisted patents that may still support an infringement claim.

Which companies have challenged Xifaxan patents?

Norwich Pharmaceuticals challenged Xifaxan patents in connection with an ANDA for rifaximin tablets. Litigation centered on patents covering rifaximin use in hepatic encephalopathy and IBS-D. The dispute reached the U.S. Court of Appeals for the Federal Circuit, which addressed obviousness and the evidentiary record concerning the claimed uses (U.S. Court of Appeals for the Federal Circuit, 2023).

The Norwich litigation demonstrates the principal generic-entry risk: a developer can establish pharmaceutical equivalence and pursue approval while remaining exposed to method-of-use patent litigation. Other ANDA applicants and potential licensees should evaluate whether their formulation, labeling, and proposed launch strategy create similar exposure.

Publicly reported settlements and commercial arrangements involving Xifaxan challengers should be reviewed on an applicant-by-applicant basis. A settlement may establish a licensed entry date, but it may also contain restrictions on indication, dosage strength, manufacturing source, or supply arrangements. A settlement date should not be treated as a general Xifaxan patent-expiration date.

What generic launch scenarios exist for Xifaxan?

Scenario 1: Full-label approval after patent litigation

A challenger obtains approval for the principal 550 mg indications and launches after prevailing in litigation or obtaining a license. This scenario creates the largest revenue impact for the originator and the greatest value for a generic sponsor.

Scenario 2: Carvedil-out labeling

A challenger obtains approval for an indication not covered by enforceable method-of-use claims. This can permit limited entry but may be commercially weak if the carved-out indication has limited market demand or if physician prescribing is concentrated in the protected uses.

Scenario 3: Settlement-based entry

A challenger receives a contractually defined launch date. The value depends on the date, whether multiple challengers receive similar rights, and whether the agreement permits authorized-generic or supply competition.

Scenario 4: Differentiated 505(b)(2) product

A sponsor develops a new dosage form, pediatric formulation, delivery system, or combination product. A 505(b)(2) route could create a distinct commercial position, but the sponsor would face clinical, formulation, patent, and labeling requirements beyond a standard ANDA.

How large is the commercial opportunity around Xifaxan excipients?

Xifaxan is one of the most commercially significant gastrointestinal rifaximin products in the U.S. Bausch's annual reports have identified Xifaxan as a major contributor to Salix revenue, with annual product sales in the billion-dollar range (Bausch Health Companies Inc., 2024).

The opportunity divides into four segments:

Opportunity	Value proposition	Main barrier
Qualified excipient supply	Secure approved-grade supply for generic and branded production	Vendor qualification and price competition
Functional excipient technology	Improve flow, disintegration, wetting, or stability	Need to prove performance without changing exposure
Generic formulation packages	Reduce development time for ANDA sponsors	Patent and bioequivalence risk
Differentiated rifaximin products	New dosage forms or patient segments	Clinical and regulatory investment

The highest-margin opportunity is a functional excipient or process package that solves a specific rifaximin problem, such as polymorph preservation, high-dose tablet compression, or dissolution reproducibility. Commodity supply of microcrystalline cellulose, talc, titanium dioxide, or colloidal silicon dioxide is less differentiated.

How strong is the Xifaxan patent estate for excipient suppliers?

Excipient suppliers generally face lower direct patent risk than finished-dose manufacturers because they sell ingredients rather than the patented drug product. Risk increases when a supplier:

• Provides a proprietary excipient system specifically claimed for rifaximin.
• Supplies a process designed to produce a patented polymorph.
• Participates in manufacturing a finished tablet.
• Receives confidential formulation information from an ANDA applicant.
• Makes technical representations that support a method-of-use or composition claim.

A supplier should separate ordinary excipient sales from formulation-development services, use contractual confidentiality controls, and conduct a claim chart against composition, polymorph, process, and use patents. A non-infringing ingredient does not eliminate risk created by the customer's finished formulation or manufacturing process.

What FDA regulatory issues affect Xifaxan excipient strategy?

FDA review will focus on the finished product's performance, not only on whether each ingredient is individually accepted for oral use. Key issues include:

• Pharmaceutical equivalence to the reference listed drug.
• Comparative dissolution across relevant media and pH conditions.
• Tablet disintegration and mechanical properties.
• Stability and solid-state form.
• Impurities and degradation products.
• Food-effect performance where required.
• Bioequivalence under the applicable FDA pathway.
• Colorant and titanium dioxide compliance.
• Supplier qualification and change control.

A change from glycerol palmitostearate to another lubricant, or from one superdisintegrant grade to another, may appear routine but can alter dissolution and tablet robustness. Excipient changes should therefore be assessed through design-of-experiments work tied to critical quality attributes.

Does biosimilar risk apply to Xifaxan?

No. Xifaxan contains rifaximin, a small-molecule antibacterial drug, not a biologic. Biosimilar competition is not the relevant pathway. The competitive routes are ANDAs, authorized generics, patent settlements, and potentially 505(b)(2) applications for differentiated dosage forms.

How does Xifaxan compare with competing gastrointestinal drugs?

Xifaxan has a distinct competitive position because it is locally acting and approved for multiple gastrointestinal indications. Competitors include lactulose and rifaximin alternatives for hepatic encephalopathy, as well as therapies for IBS-D such as eluxadoline, loperamide, bile-acid sequestrants, and symptomatic treatments.

Product category	Principal competitive factor	Excipient opportunity
Rifaximin generic	Patent timing and bioequivalence	High
Lactulose products	Cost and tolerability	Moderate
Eluxadoline	Indication-specific efficacy and safety	Low relative to Xifaxan
OTC antidiarrheals	Price and access	Low
New GI delivery systems	Local exposure and convenience	Potentially high

Xifaxan's commercial defensibility is strongest where the product's indication-specific clinical value and patent protection overlap. Price competition becomes more severe once a legally cleared generic reaches the principal 550 mg uses.

Key Takeaways

• Xifaxan uses a conventional tablet excipient system, but rifaximin's poor solubility and solid-state behavior make formulation performance strategically important.
• The most valuable excipient opportunities involve dissolution control, polymorph preservation, high-dose compression, and manufacturing robustness.
• Commodity excipient supply is a lower-margin opportunity than proprietary formulation or process support.
• Xifaxan's primary competitive barriers have included polymorph, composition, and method-of-use patents.
• The 550 mg tablet carries the greatest commercial value and the greatest patent and bioequivalence risk.
• Norwich's litigation illustrates how method-of-use patents can delay or restrict generic launch even when a generic formulation is technically feasible.
• Biosimilar risk does not apply because rifaximin is a small molecule.
• Excipient suppliers should distinguish ingredient sales from formulation services and review the finished-product patent position.
• Xifaxan revenue exposure is substantial because the product contributes annual sales in the billion-dollar range for Bausch's Salix business.
• The strongest commercial strategy is a technically differentiated, regulatory-compatible excipient platform that improves product robustness without materially changing rifaximin exposure.

Frequently Asked Questions

Can a generic Xifaxan manufacturer change the excipients?

Yes. An ANDA applicant may use different inactive ingredients if the finished product meets applicable pharmaceutical equivalence, quality, dissolution, labeling, and bioequivalence requirements. The change can still create patent or process risk.

Which excipient is most important for Xifaxan dissolution?

Sodium starch glycolate is likely to have a major effect on disintegration, while wetting, lubricant level, particle size, and granulation conditions also influence dissolution. No single excipient determines performance independently.

Is rifaximin polymorph control a commercial barrier?

Yes. Polymorph control can affect solubility, dissolution, stability, and patent exposure. It is a central technical issue for both API suppliers and finished-dose developers.

Can an excipient company license a Xifaxan formulation platform?

Potentially, but the license must address formulation claims, process claims, confidential know-how, supply rights, regulatory data, and any method-of-use restrictions. Ingredient supply alone does not grant rights to commercialize a rifaximin product.

Does a new rifaximin suspension create a separate commercial opportunity?

It could support pediatric, dysphagia, or other patient segments, but a suspension would require evaluation of dose uniformity, chemical and microbiological stability, palatability, preservative strategy, local exposure, and the applicable FDA regulatory pathway.

References

Bausch Health Companies Inc. (2024). 2023 annual report. https://ir.bausch.com/

U.S. Court of Appeals for the Federal Circuit. (2023). Salix Pharmaceuticals, Ltd. v. Norwich Pharmaceuticals Inc., No. 21-2158.

U.S. Food and Drug Administration. (2024a). Xifaxan (rifaximin) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/